Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Campus Vienna Biocenter - Progress on Alzheimer’s Vaccine

16.09.2005


An innovative vaccination can significantly reduce deposits of the substances in the brain responsible for causing Alzheimer’s disease. This result was disclosed today by Affiris GmbH, a company located at the Campus Vienna Biocenter, Austria. The rapid progress during the pre-clinical development phase has already enabled the Vienna-based company, although having operated only since April 2004, to plan clinical trials for 2006, and thus proves the international competitiveness of the Campus Vienna Biocenter.



Beta-amyloids are pathological fragments of a normal brain protein. They are responsible for the development of Alzheimer’s disease, as they cause the death of brain cells. Amyloid fragments are found in large amounts in the cerebral fluid of Alzheimer patients. Deposits are formed in the brain over the years, thus creating the plaque structures typical of Alzheimer’s disease. It has not yet been completely clarified whether plaque formation or the soluble beta-amyloids are the causative agents for Alzheimer’s disease.

Tailor-made Vaccine


The Vienna-based company Affiris is now reporting that it has succeeded in significantly reducing Alzheimer plaques by at least two-thirds in pre-clinical models by means of an innovative vaccine. CEO Dr. Walter Schmidt explains the important feature of the vaccination strategy: "Alzheimer’s is caused by a fragment of one of the ubiquitous proteins of cerebral cells. If one wants to combat Alzheimer immunologically it is essential to generate antibodies which are targeted against the beta-amyloids, but which leave the normal constituent of the cerebral cells unharmed, since the latter would induce an autoimmune disease. In keeping with this, Affiris´ vaccine approach has been shown to be highly specific for beta amyloids and not to react with the normal constituent of cerebral cells."

Thus, the Affiris approach not only avoids an autoimmune disease, but also offers the advantage of targeting simultaneously both the plaques and the soluble beta-amyloid fraction. Therefore, whether the soluble or plaque forms - or both - are responsible for causing the disease is not ultimately crucial for the vaccine’s success. The additional proof that the vaccine induces antibodies, which are active against plaques in human tissue samples, and the first data collected on the toxicology profile have further contributed to built a secure basis for Affiris to schedule the first trials on patients for 2006.

Biotech with Economics

Beside its scientific success Affiris also boasts important economic advantages: low costs and short manufacturing times for its vaccine. In the words of Dr. Schmidt: "Our substances are produced at low costs and a building-block system is used to form the vaccine. The effective component is synthetically manufactured and combined with a carrier substance isolated from natural resources. Both together form the actual vaccine and a standard adjuvant is added to strengthen the immune response."

The fact that the management has taken these important economic aspects into consideration from the very beginning is also due to the comprehensive biotech experiences at the Campus Vienna Biocenter. After all, numerous biotech companies and research institutes are situated at the Campus Vienna Biocenter, in addition to the FH Campus Wien (biotechnology), the Life Science Departments of the University of Vienna and the Medical University of Vienna, all sharing both resources and experiences and thus contributing to the international success of this location.

About AFFiRiS (September 2005):

AFFiRiS develops peptide-based vaccines for the treatment of Alzheimer’s disease and atherosclerosis. The company has established platform technologies and registered seven patents. 12 employees work in a 6,500 sqf rented laboratory facility on the Campus Vienna Biocenter.

About the Campus Vienna Biocenter (September 2005):

The Campus Vienna Biocenter is one of the largest R&D clusters in Austria with approx. 1,000 scientists from 40 nations at 16 organisations. Academic departments (University of Vienna, Medical University of Vienna, subsumed in the Max F. Perutz Laboratories), private research institutes (IMP - Institute of Molecular Pathology) and institutes of the Austrian Academy of Sciences (IMBA - Institute of Molecular Biotechnology, GMI - Gregor Mendel Institute) are also located here along with commercial R&D companies, service companies and training course centres.

Till C. Jelitto | alfa
Further information:
http://www.prd.at
http://www.affiris.com
http://www.viennabiocenter.com

More articles from Health and Medicine:

nachricht Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München

nachricht Second cause of hidden hearing loss identified
20.02.2017 | Michigan Medicine - University of Michigan

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Microhotplates for a smart gas sensor

22.02.2017 | Power and Electrical Engineering

Scientists unlock ability to generate new sensory hair cells

22.02.2017 | Life Sciences

Prediction: More gas-giants will be found orbiting Sun-like stars

22.02.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>